- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04070183
POST Facilitation for Community Dwelling Older Adults (POST-RCT) (POST-RCT)
POST Facilitation for Community Dwelling Older Adults With and Without Dementia
Study Overview
Status
Intervention / Treatment
Detailed Description
The POLST paradigm, which stands for Physician Orders for Life Sustaining Treatment, was developed to address inconsistencies between care received and patient and family wishes for treatment, with an aim to increase concordant care. The POLST paradigm is nationally recognized and implemented in a number of states under different names. In Indiana, for example, it is called "Physician Orders for Scope of Treatment" (POST). Because of this, all patient facing materials will refer to POST, however, we use the terms POST and POLST interchangeably in this proposal.
POLST affects delivery of medical interventions and improved concordance between patient preferences and care received.
Our specific aims are:
To test the effect of high quality POLST Facilitation delivered in the home compared to attention control on:
a.discordance between preferences for treatment and treatments received in the subsequent 12 months (primary outcome).
To test the effect of POLST Facilitation on intermediate outcomes including:
- The proportion of patients with a completed POLST form in the electronic medical record within 3 months of POLST Facilitation
- Decision quality regarding ACP as measured by the Decisional Conflict Scale, the advance care planning (ACP) Engagement Survey,and the POLST knowledge survey
To test the effect of a POLST Facilitation on secondary outcomes of cost and end-of-life care including:
- Receipt of life-sustaining interventions or hospice within the 30 days prior to death, for patients who die during the year after POLST Facilitation
- The psychological well-being (anxiety, depression,and post traumatic stress) of surrogate decision makers after the patient's death
- The cost effectiveness of POLST Facilitation for the prevention of ICU admissions and hospitalizations
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- IU Health Methodist Hospital
-
Indianapolis, Indiana, United States, 46202
- Eskenazi Health
-
Indianapolis, Indiana, United States, 46202
- IU Health University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients:
- 65 or older
- have decision making capacity OR a qualified surrogate decision maker
must meet one of the following index scores:
- Gagne Mortality Index score of 7 or greater (30% mortality risk)
- Medicare Criteria for Hospice Admission: Functional Assessment Staging Tool (FAST) Index (Advanced Alzheimer's disease and related dementia) 7c or higher plus one or more comorbid conditions.
- Seattle Heart Failure Model (congestive heart failure): score conferring a one-year mortality risk of 30% or greater
- Eastern Cooperative Oncology Group (ECOG) performance status (metastatic cancer): Patients with an impaired performance score (greater than zero)
- Liu Comorbidity Index (End Stage Renal Disease): Patients with a score of 10 or greater
- blood results (B), age (A), respiratory variables (airflow obstruction, exacerbations, smoking) (R) and comorbidities (C) (BARC) Index for chronic obstructive pulmonary disease (COPD): high risk group
- Model for End Stage Liver Disease (MELD) Index
- must be able to pass consent verification
- must not be enrolled in hospice
- must not have an acute illness
- must give patient's provider opportunity to review the "surprise question" (e.g. would you be surprised if the patient died in the next year) to confirm anticipated mortality within the next year (14 days to respond)
- must not have a POST form on file.
Exclusion criteria:
- lack of a patient or surrogate decision maker who can participate in POLST facilitation (for non-decisional patients a health care representative (HCR) or designated power of attorney for health care (DPOA-HC) must enroll with them)
- patients who are already enrolled in hospice
- patients or surrogates who cannot pass consent verification
- patients or surrogates who do not speak English
- patients with a POST form on file
- patients who are not community-dwelling
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Attention Control (Home Safety Evaluation)
A nurse will complete a home visit with the patient and their surrogate decision maker or other family member (if they've designated one), in which he or she will provide suggestions on how to improve the safety of the patient's home.
|
Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and carbon monoxide (CO) detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
|
|
Experimental: Intervention (POST Facilitation)
A nurse will complete a home visit with the patient and their surrogate decision maker or other family (if they've designated one), in which he or she will provide education about the POST form.
The POST facilitators will be nurses trained using the Respecting Choices Advanced Steps model.
|
Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected.
The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions.
Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care.
The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Discordance between treatment preferences and treatment received 12 months after POST Facilitation
Time Frame: Assessed 12 months from the date that the patient receives POST facilitation or home safety evaluation
|
Chart review and comparative statistics will be used to determine discordance between patient/family preferences and care received at the end of life.
|
Assessed 12 months from the date that the patient receives POST facilitation or home safety evaluation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients who have a completed POST form 3 months after receiving POST Facilitation
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
Chart review and comparative statistics will be used to determine any correlations between intervention and completion of a POST form
|
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
|
Decision conflict
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
Decisional Conflict Scale (DCS) The DCS is used to assess decision conflict Scores range from 0 (no decisional conflict) to 100 (high decisional conflict) 0= 'strongly agree'; 1= 'agree'; 2= 'neither agree nor disagree'; 3= 'disagree'; 4= 'strongly disagree'. TOTAL SCORE 16 items are: a) summed; b) divided by 16; and c) multiplied by 25 Other papers may present scores ranging from 1 [low decisional conflict] to 5 [high decisional conflict]. |
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
|
Effect of the intervention on cost and end of life care (EOL) for patients who die within 12 months of the intervention
Time Frame: Assessed by chart review 12 months from the date that the participant receives POST facilitation or a home safety evaluation
|
Will use comparative statistics to determine any correlations between intervention and EOL care (life sustaining treatments received and hospice enrollment within 30 days of death)
|
Assessed by chart review 12 months from the date that the participant receives POST facilitation or a home safety evaluation
|
|
Effect of the intervention on psychological well-being (anxiety)
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
Generalized Anxiety Disorder- 7 (GAD-7) (7 item inventory of anxiety)- assesses subject's self-reported anxiety for the last two weeks. Scores range from 0-21 0= 'Not at all'; 1= 'Several Days'; 2= 'More than half the days'; 3= 'Nearly every day' Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. When used as a screening tool, further evaluation is recommended when the score is 10 or greater. Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a specificity of 82% for GAD. |
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
|
Effect of the intervention on psychological well-being (depression)
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
Patient Health Questionnaire-8 (PHQ-8: item inventory of depression) Scores range from 0-24 *note that this scale is adapted from the PHQ-9, to remove the question about suicidal ideation. 0= 'Not at all'; 1= 'Several Days'; 2= 'More than half the days'; 3= 'Nearly every day' Higher scores indicate higher severity of depressive symptoms. |
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
|
Effect of the intervention on psychological well-being (post traumatic stress)
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
(IES-R (Impact of Events Scale- Revised- inventory for PTSD) Scores range from 0-88 0= 'Not at all'; 1= 'A little bit'; 2= 'Moderately'; 3= 'Quite a bit'; 4= 'Extremely' The Impact of Event Scale-Revised (Weiss & Marmar, 1997) is a 22-item scale which is rated on a 0 (not at all) to 4 (extremely) scale with respect to how distressing each item has been during the past week.
Scale scores are formed for the three subscales, which reflect intrusion (8 items), avoidance (8 items), and hyperarousal (6 items).
|
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
|
Decision quality- ACP engagement
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
Advance Care Planning (ACP) engagement survey
|
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
|
Decision quality- POLST Knowledge
Time Frame: Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
POLST Knowledge Survey
|
Assessed 3 months from the date that the participant receives POST facilitation or a home safety evaluation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alexia M Torke, MD, MS, Regenstrief Institute, Indiana University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1905850231
- R01AG056618 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
Clinical Trials on Home Safety Evaluation
-
Rush University Medical CenterCompletedParkinson Disease | TelemedicineUnited States
-
US Department of Veterans AffairsBoston Medical CenterCompleted
-
Penn State UniversityEnrolling by invitation
-
Beth Israel Deaconess Medical CenterNational Cancer Institute (NCI)CompletedBreast Cancer ScreeningUnited States
-
Abramson Cancer Center at Penn MedicineCompleted
-
The University of Texas Health Science Center,...The University of Texas Health Science Center at TylerCompletedParenting | Motivational Interviewing | Maltreatment/AbuseUnited States
-
Johns Hopkins UniversityNational Institute on Aging (NIA)CompletedDementiaUnited States
-
University of ChicagoCompletedCommunication | Behavior | LanguageUnited States
-
Rigshospitalet, DenmarkRecruitingAcute Myeloid Leukaemia (AML)Denmark